The metastatic LMD prostate tumour cells express EGFP under the transcriptional control of the TAP-1 promoter28, where an increase in EGFP expression correlates with an increase in both TAP-1 and MHC-I expression, and where elevated level of these components is associated with higher recognition of the tumour cells by T cells. The gene discussed is TAP1; the disease is prostate neoplasm.